$KPTI it's challenged by toxicity/adoption concerns short term; how quick the results of Boston study translate into new TRx for 2nd line , execution by its commercial organization (2/3Q), Europe approval/partnership and results of COVID study are major catalysts in the next 6-8 months.
  • 3
3 Likes